Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 551 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How you can do your part in the AI transformation of... October 7, 2025 Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... March 6, 2020 Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... June 19, 2019 Determining Fluid Requirements March 26, 2021 Load more HOT NEWS Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies Will politics keep us from accessing EU science funding? Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση Mom Of Two Diagnosed With Breast Cancer At 31: “I Just...
